The psychoactive brew Ayahuasca has a central role in the traditional medicines of the indigenous people of the Amazon basin and in recent decades has generated significant research interest among the academic community along with the revival of psychedelic medicine. The therapeutic community Takiwasi, located in Peru, leads this movement in its dedication to treatment of substance use...
Several studies have linked myelin abnormalities with neuropsychiatric disorders; others have implicated psychedelics as a potential therapeutic for such conditions. One risk factor for these demyelinating disorders is a mutation in the Apolipoprotein E gene known as APOE4. This variant impedes the cholesterol regulation of oligodendrocytes responsible for the myelination, or insulation, of...
Mindfulness-based cognitive therapy (MBCT) has emerged as a promising intervention for generalized anxiety disorder (GAD). This study evaluated MBCT's effectiveness for GAD and examined whether childhood maltreatment moderates its impact. Individuals with GAD were randomized to receive one of two 8-week interventions, either MBCT in-person or psychoeducation on-line (n = 27 per group). At...
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potential mechanism underlying their therapeutic benefits may involve a reversal of maladaptive plasticity induced by drug exposure. Here, we identify physiological, behavioral, and epigenetic impacts of lysergic acid diethylamide (LSD) on morphine-treated...
Quality spaces promise to represent mental qualities objectively. That objectivity is compromised, however, if quality spaces are constructed by subjective introspective access, which is impressionistic. But mental qualities also have a robust and objective connection to perceptual discrimination. So quality spaces can be constructed in a fully objective way by appeal to their role in...
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....
This article analyses the diagnostic criteria for borderline personality disorder as defined in the 5th edition of Diagnostic and Statistical Manual of Mental Disorders and the 11th revision of International Classification of Diseases. The combination of categorical and dimensional diagnostic models improves its validity, which meets the needs of clinical practice. At the same time, the...
The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the synergistic benefits of combining psilocybin (PSIL) with...
Abstract Spontaneous thoughts and experiences, such as dreaming and mind wandering, form a significant part of our conscious mental lives. Yet, the precise phenomenological and content-related similarities and differences between dreaming and waking mind wandering remain insufficiently understood. In this study, we address this gap by comparing 340 dreaming and mind wandering questionnaire...
Background/Objectives: D-lysergic acid diethylamide (D-LSD) is under investigation as a potential therapeutic strategy for alcohol use disorder (AUD). However, the extreme light sensitivity of D-LSD presents a significant challenge in developing suitable pharmaceutical forms, particularly for clinical trial settings. This study proposes a liquid-filled capsule formulation designed to provide...